Steven J Cohen
Overview
Explore the profile of Steven J Cohen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
3643
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Savitch S, Grenda T, Scott W, Cowan S, Posey 3rd J, Mitchell E, et al.
J Gastrointest Surg
. 2020 Jun;
25(3):581-592.
PMID: 32500418
Background: Treatment guidelines for stage I-III esophageal cancer indicate that management should include surgery in appropriate patients. Variations in utilization of surgery may contribute to racial differences observed in survival....
12.
Vijayvergia N, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh R, et al.
Br J Cancer
. 2020 Mar;
122(9):1309-1314.
PMID: 32152503
Background: Metastatic high-grade neuroendocrine neoplasms (G3NENs) have limited treatment options after progression on platinum-based therapy. We addressed the role of Pembrolizumab in patients with previously treated metastatic G3NENs. Methods: Two...
13.
Jain R, Vijayvergia N, Devarajan K, Lewis B, Denlinger C, Cohen S, et al.
J Geriatr Oncol
. 2020 Jan;
11(4):640-646.
PMID: 31917116
Background: While a number of landmark clinical trials have led to the approval of combination chemotherapy regimens for metastatic pancreatic adenocarcinoma (mPC), older patients are underrepresented in these studies. We...
14.
Davis S, Cardin D, Shahda S, Lenz H, Dotan E, ONeil B, et al.
Invest New Drugs
. 2019 Jul;
38(3):821-830.
PMID: 31338636
Vantictumab is a fully human monoclonal antibody that inhibits Wnt pathway signaling through binding FZD1, 2, 5, 7, and 8 receptors. This phase Ib study evaluated vantictumab in combination with...
15.
Mayer R, Hochster H, Cohen S, Winkler R, Makris L, Grothey A
Cancer Chemother Pharmacol
. 2018 Oct;
82(6):961-969.
PMID: 30350179
Purpose: Trifluridine/tipiracil (FTD/TPI; TAS-102, Lonsurf®), a novel form of chemotherapy for metastatic colorectal cancer (mCRC), has shown clinical benefit in the global, phase III RECOURSE trial, regardless of patient age....
16.
Beatty G, Shahda S, Beck T, Uppal N, Cohen S, Donehower R, et al.
Oncologist
. 2018 Aug;
24(1):14-e10.
PMID: 30115734
Lessons Learned: Itacitinib in combination with -paclitaxel plus gemcitabine demonstrated an acceptable safety profile with clinical activity in patients with advanced solid tumors including pancreatic cancer.The results support future studies...
17.
Dotan E, Cohen S, Starodub A, Lieu C, Messersmith W, Simpson P, et al.
J Clin Oncol
. 2017 Aug;
35(29):3338-3346.
PMID: 28817371
Purpose The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an...
18.
Kennedy A, Ball D, Cohen S, Cohn M, Coldwell D, Drooz A, et al.
J Gastrointest Oncol
. 2017 Mar;
8(1):70-80.
PMID: 28280611
Background: Patients with liver metastatic colorectal cancer (mCRC) often benefit from receiving Y-microsphere radioembolization (RE) administered via the hepatic arteries. Prior to delivery of liver-directed radiation, standard laboratory tests may...
19.
20.
Vijayvergia N, Cohen S
J Gastrointest Oncol
. 2016 Oct;
7(5):727-737.
PMID: 27747087
Pancreatic adenocarcinoma is the fourth leading cause of cancer related death in the United States. Most patients are diagnosed at a late stage and despite recent advances in chemotherapeutic approaches,...